Wang Yifan, Aivalioti Evmorfia, Stamatelopoulos Kimon, Zervas Georgios, Mortensen Martin Bødtker, Zeller Marianne, Liberale Luca, Di Vece Davide, Schweiger Victor, Camici Giovanni G, Lüscher Thomas F, Kraler Simon
Center for Molecular Cardiology, University of Zurich, Schlieren, Switzerland.
Department of Clinical Therapeutics, Alexandra Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
Eur J Clin Invest. 2025 Apr;55 Suppl 1:e70017. doi: 10.1111/eci.70017.
Cardiovascular diseases remain the leading cause of global morbidity and mortality. Validated risk scores are the basis of guideline-recommended care, but most scores lack the capacity to integrate complex and multidimensional data. Limitations inherent to traditional risk prediction models and the growing burden of residual cardiovascular risk highlight the need for refined strategies that go beyond conventional paradigms. Artificial intelligence and machine learning (ML) provide unique opportunities to refine cardiovascular risk assessment and surveillance through the integration of diverse data types and sources, including clinical, electrocardiographic, imaging and multi-omics derived data. In fact, ML models, such as deep neural networks, can handle high-dimensional data through which phenotyping and cardiovascular risk assessment across diverse patient populations become much more precise, fostering a paradigm shift towards more personalized care. Here, we review the role of ML in advancing cardiovascular risk assessment and discuss its potential to identify novel therapeutic targets and to improve prevention strategies. We also discuss key challenges inherent to ML, such as data quality, standardized reporting, model transparency and validation, and discuss barriers in its clinical translation. We highlight the transformative potential of ML in precision cardiology and advocate for more personalized cardiovascular prevention strategies that go beyond previous notions.
心血管疾病仍然是全球发病和死亡的主要原因。经过验证的风险评分是指南推荐治疗的基础,但大多数评分缺乏整合复杂多维数据的能力。传统风险预测模型固有的局限性以及残余心血管风险负担的不断增加,凸显了超越传统模式的精细策略的必要性。人工智能和机器学习(ML)通过整合包括临床、心电图、影像和多组学衍生数据在内的多种数据类型和来源,为优化心血管风险评估和监测提供了独特机会。事实上,诸如深度神经网络等ML模型能够处理高维数据,借此在不同患者群体中进行表型分析和心血管风险评估变得更加精确,推动了向更个性化治疗模式的转变。在此,我们回顾ML在推进心血管风险评估中的作用,并讨论其识别新型治疗靶点和改进预防策略的潜力。我们还讨论了ML固有的关键挑战,如数据质量、标准化报告、模型透明度和验证,并探讨其临床转化中的障碍。我们强调ML在精准心脏病学中的变革潜力,并倡导超越以往观念的更个性化心血管预防策略。